AI assistant
Sending…
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2025
Aug 28, 2025
33148_dirs_2025-08-27_14a142c0-8239-4275-936c-712d6f636da4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-08-27
Reporting Person: Bjork Elisabeth (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-27 | Common Stock | P | 10000 | $3.41 | Acquired | 40000 | Direct |
Footnotes
F1: Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026.
More from ROCKET PHARMACEUTICALS, INC.
Merger & Acquisition
2026
May 28
Regulatory Filings
2026
May 21
Regulatory Filings
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 6
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 27
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Feb 26
Annual Report
2026
Feb 26
Director's Dealing
2026
Feb 20